Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
100%(2 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

unknown125%
recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

NCT06680128
completednot_applicable

Flavivirus Cross-priming Potential of IMOJEV

NCT03920111
unknownphase_2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

NCT05568953
completedphase_3

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

NCT01900444

Clinical Trials (4)

Showing 4 of 4 trials
NCT06680128Phase 1

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Recruiting
NCT03920111Not Applicable

Flavivirus Cross-priming Potential of IMOJEV

Completed
NCT05568953Phase 2

An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity

Unknown
NCT01900444Phase 3

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Completed

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4